Biotin
Biotin (Vitamin B7)
Essential B vitamin for hair, skin, and nail health, plus metabolic support for energy production.
Biotin (Vitamin B7) is a water-soluble B vitamin essential for fatty acid synthesis, gluconeogenesis, and amino acid metabolism. While true deficiency is rare, supplementation is popular for hair, skin, and nail health. Evidence is strongest for brittle nail syndrome; hair benefits are less proven but widely reported anecdotally.
Mechanisms of Action
Keratin Infrastructure
Supports protein building blocks of hair and nails
Metabolic Cofactor
Essential for energy metabolism
Recommended Dose
2500-5000mcg (2.5-5mg) for hair/nails
Optimal Timing
- Any time of day
Can be taken without food
Best Form
Biotin capsules or tablets
Alternatives: Gummies, Combined hair/skin/nail formulas
Standalone biotin is most economical. Higher doses (5000-10000mcg) are common for cosmetic purposes.
Duration
Minimum: 12 weeks
Optimal: 24 weeks
Cycling: Not required
Note: Water-soluble, can be taken any time. Consistent daily use is key.
Personalized Dosage Calculator
Get a dosage recommendation tailored to your body weight, age, goals, and health profile.
Set up your health profile for personalized recommendations
Stronger Nails
Improved nail thickness and reduced brittleness
Hair Quality
May improve hair thickness and reduce shedding
Safe at normal doses; may help prevent deficiency
Who Should NOT Take This
- Known allergy or hypersensitivity to Biotin or related compounds
- May interfere with lab test results (thyroid panels, troponin, hormone assays) — inform healthcare providers before blood tests
Drug Interactions
HIGH BIOTIN INTERFERES WITH LAB TESTS — stop 48-72 hours before bloodwork
May reduce biotin levels
Biotin deficiency despite supplementation
Possible Side Effects
Tip: Reduce dose
Warnings
- CRITICAL: Stop biotin 48-72 hours before any blood tests
- Can cause FALSE lab results for thyroid, cardiac troponin, hormones
- Hair/nail effects take 3-6 months to appear
- Evidence for hair growth is limited outside of deficiency
Top studies from 40+ peer-reviewed papers
Sui Z et al. • Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia (2023)
“The results of this study provide the necessary quantitative information for both the rational clinical use of drugs and future clinical trials in primary progressive multiple sclerosis.”
Key Findings:
- Among these, ocrelizumab showed outstanding performance, with wCDP% of 72.6 at 96 weeks, while the proportions of rest of the drugs ranged between approximately 55-70%.
- The results of this study provide the necessary quantitative information for both the rational clinical use of drugs and future clinical trials in primary progressive multiple sclerosis.
- Further research warranted to confirm findings
Gaffney PJ et al. • Multiple sclerosis and related disorders (2025)
“Although meta-analysis showed no significant effect of vitamins A, B1, B6, B7, B12, and D on several visual parameters, improvements observed in individual studies point to the essential role of vitamin sufficiency in ON.”
Key Findings:
- The effect of MD1003 (high-dose biotin), vitamin A, and vitamin D on retinal nerve fiber layer (RNFL) thickness from pooled results showed a mean change of 0.15 (SMD 0.15, 95 % CI, -0.33 to 0.64, I2 = 61 %, τ² = 0.11, p = 0.08), which was not significant.
- Meta-analysis of visual acuity due to MD1003 and vitamin A from two studies showed a mean change of 0.01 (SMD 0.01, 95 % CI, -0.34 to 0.35, I2 = 0 %, τ² = 0, p = 0.36).
- Significant improvements in RNFL thickness due to vitamin A, visual acuity due to vitamins B1, B6, and B12, foveal sensitivity due to vitamins B1, B6, and B12, and the rate of conversion of ON to MS due to vitamin D were observed in individual studies.
Espiritu AI et al. • Multiple sclerosis and related disorders (2021)
“A moderate certainty of evidence suggests a potential benefit in favor of HDB administered for 12 to 15 months in terms of ITW25 in patients with PMS.”
Key Findings:
- Pooled data for ITW25 at 12 to 15 months yielded statistical significance (RR 2.06; 95% CI 1.04-4.09; 2 trials; 796 participants; I2 = 0%) [moderate COE] favoring HDB among patients with PMS.
- At 12 to 15 months, no significant differences were found in terms of mean change in EDSS (MD -0.06; 95% CI -0.14-0.02; 2 studies; 796 participants; 889 participants; I2 = 68%) among patients with PMS.
- Synthesized data on incidence of any AEs (RR 0.98; 95% CI 0.92-1.04; 3 trials; I2 = 0%) [high COE] and any serious AEs (RR 0.98; 95% CI 0.77-1.24; 3 trials; 889 participants; I2 = 0%) [moderate COE] were not significantly different between HDB and placebo groups.
- Out of 662 pooled patients in the HDB group, 31 patients (4.7%) were found to have laboratory test interference compared to zero event in the pooled placebo group [high COE].
Lira Neto FT et al. • Fertility and sterility (2021)
“We concluded that pooled results from studies including infertile men with clinical varicocele indicated that varicocelectomy reduced the SDF rates.”
Key Findings:
- Varicocelectomy was associated with reduced postoperative SDF rates (WMD -7.23%; 95% CI: -8.86 to -5.59; I2 = 91%).
- The treatment effect size was moderate (Cohen's d = 0.68; 95% CI: 0.77 to 0.60).
- Meta-regression analysis demonstrated that SDF decreased after varicocelectomy as a function of preoperative SDF levels (coefficient: 0.23; 95% CI: 0.07 to 0.39).
Parks NE et al. • The Cochrane database of systematic reviews (2020)
“There are a variety of controlled trials addressing the effects of dietary interventions for MS with substantial variation in active treatment, comparator, and outcomes of interest.”
Key Findings:
- Among four trials comparing PUFAs with MUFAs, there may be little to no difference in global impression of deterioration (RR 0.85, 95% CI 0.71 to 1.03; 4 studies, 542 participants; 40% in the PUFA group versus 47% in the MUFA group; low-certainty evidence).
- In two trials comparing different PUFAs (omega-3 versus omega-6), there may be little to no difference in relapses (RR 1.02, 95% CI 0.62 to 1.66; 2 studies, 129 participants; 30% in the omega-3 versus 29% in the omega-6 group; low-certainty evidence).
- Among three trials comparing omega-3 with omega-6, there may be little to no difference in change in disability progression, measured as mean change in Expanded Disability Status Scale (EDSS) (mean difference (MD) 0.00, 95% CI -0.30 to 0.30; 3 studies, 166 participants; low-certainty evidence).
- In one trial comparing omega-3 with omega-6, there was likely no difference in global impression of deterioration (RR 0.99, 95% CI 0.51 to 1.91; 1 study, 86 participants; 29% in omega-3 versus 29% in omega-6 group; moderate-certainty evidence).
Study Type Distribution
Goals This Supplement Supports
This information is for educational purposes only and is not intended as medical advice. Always consult a qualified healthcare provider before starting any supplement.